Company RXi Pharmaceuticals Corp Nasdaq
Equities
US74979C8082
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 18/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 14/09/17 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 09/11/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 18/06/12 |
Director/Board Member | 73 | 01/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 17/04/13 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 06/06/17 |
Robert Ferrara
BRD | Director/Board Member | 73 | 30/09/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 4,591,700 | 4,564,638 ( 99.41 %) | 0 | 99.41 % |
Company contact information
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508-767-3861
http://www.phiopharma.comSector
1st Jan change | Capi. | |
---|---|---|
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+41.82% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |